. 2021 Dec 2;12:751321. doi: 10.3389/fphar.2021.751321

TABLE 6.

Composition of nanostructured lipid carrier (NLC) and nanoemulsion (NE) formulations, respective physicochemical characterization, and evaluation of their performance.

Formulation	Lipid phase		Aqueous phase		Escitalopram paroxetine % (w/w)	Borneol (50 mg/ml)	PS (nm)	PdI	ZP (mV)	EE (%)		DL (%)
Formulation	Precirol^® ATO 5% (w/w)	Lauroglycol™ 90% (w/w)	Tween 80% (w/w)	Water %	Escitalopram paroxetine % (w/w)	Borneol (50 mg/ml)	PS (nm)	PdI	ZP (mV)	Escitalopram	Paroxetine	Escitalopram	Paroxetine
NLC1	5.00	5.00	2.50	85.7	0.900	—	546 ± 16.0	0.640	12.0 ± 0.210	17.6 ± 6.86	60.3 ± 9.97	1.01 ± 0.580	3.80 ± 1.42
NLC1	5.00	5.00	2.50	85.7	0.900	—	546 ± 16.0	0.640	12.0 ± 0.210	17.6 ± 6.86	60.3 ± 9.97	1.01 ± 0.580	3.80 ± 1.42
NLC2	2.50	7.50	2.50	85.7	0.900	—	165 ± 2.01	0.273	11.2 ± 0.400	44.5 ± 5.23	83.1 ± 8.49	4.44 ± 0.700	5.93 ± 1.04
NLC2	2.50	7.50	2.50	85.7	0.900	—	165 ± 2.01	0.273	11.2 ± 0.400	44.5 ± 5.23	83.1 ± 8.49	4.44 ± 0.700	5.93 ± 1.04
NE	0.00	10.0	2.50	85.7	0.900	—	188 ± 2.10	0.172	17.6 ± 0.890	39.2 ± 7.50	81.1 ± 8.91	2.67 ± 1.58	5.78 ± 2.16
NE	0.00	10.0	2.50	85.7	0.900	—	188 ± 2.10	0.172	17.6 ± 0.890	39.2 ± 7.50	81.1 ± 8.91	2.67 ± 1.58	5.78 ± 2.16
BorNLC	2.50	7.50	2.50	85.7	0.900	50.0 µl	160 ± 2.01	0.273	11.2 ± 0.400	33.9 ± 0.200	78.8 ± 1.06	1.8 ± 0.23	4.00 ± 0.0400
BorNLC	2.50	7.50	2.50	85.7	0.900	50.0 µl	160 ± 2.01	0.273	11.2 ± 0.400	33.9 ± 0.200	78.8 ± 1.06	1.8 ± 0.23	4.00 ± 0.0400

DL, drug loading; EE, entrapment efficiency; PdI, polydispersity index; PS, particle size; ZP, zeta potential.